Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy-Reference-Cited by-同舟云学术

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Published:2015-11-20 Issue:5 Volume:57 Page:1044-1053
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lew Thomas E.,Cheah Chan Y.,Carney Dennis A.,Prince H. Miles,Wolf Max,Bazargan Ali,Januszewicz E. Henry,Filshie Robin,Westerman David,Seymour John F.,Tam Constantine S.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1096353

Reference37 articles.

1. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology

2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

3. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

4. The National Cancer Data Base Report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia

5. ESH–SIOG International Conference on Haematological Malignancies in the Elderly

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51;Cell Death & Disease;2021-11

2. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma;Annals of Oncology;2018-03

3. Management of elderly and unfit patients with chronic lymphocytic leukemia;Expert Review of Hematology;2016-11-21

4. Cyclophosphamide/fludarabine/rituximab;Reactions Weekly;2016-07

5. Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?;Leukemia & Lymphoma;2016-04-20